- Home
- CRM vs GILD Comparison
CRM vs GILD Comparison
Compare CRM & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRM | GILD |
|---|---|---|
| Founded | 1999 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.9B | 184.4B |
| IPO Year | 2003 | 2001 |
Fundamental Metrics
Financial Performance| Metric | CRM | GILD |
|---|---|---|
| Price | $185.53 | $139.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 36 | 18 |
| Target Price | ★ $279.74 | $146.50 |
| AVG Volume (30 Days) | ★ 11.3M | 4.9M |
| Earning Date | 02-25-2026 | 04-23-2026 |
| Dividend Yield | 0.94% | ★ 2.35% |
| EPS Growth | 22.64 | ★ 1684.21 |
| EPS | ★ 7.80 | 6.78 |
| Revenue | $8,391,984,000.00 | ★ $24,689,000,000.00 |
| Revenue This Year | $12.20 | $4.69 |
| Revenue Next Year | $9.49 | $5.95 |
| P/E Ratio | $23.97 | ★ $20.59 |
| Revenue Growth | ★ 25.87 | 9.98 |
| 52 Week Low | $174.57 | $95.30 |
| 52 Week High | $296.05 | $157.29 |
Technical Indicators
Market Signals| Indicator | CRM | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 44.35 | 46.31 |
| Support Level | $177.41 | $108.90 |
| Resistance Level | $204.86 | $149.38 |
| Average True Range (ATR) | 6.43 | 3.41 |
| MACD | -0.01 | -0.14 |
| Stochastic Oscillator | 33.54 | 45.40 |
Price Performance
Historical ComparisonAbout CRM Salesforce Inc.
Salesforce provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).